Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 7, 2015, Pages 1589-1596

  Miao, Ji ^a   Manthena, Praveen V ^a   Haas, Mary E ^a   Ling, Alisha V ^a   Shin, Dong Ju ^a   Graham, Mark J ^b   Crooke, Rosanne M ^b   Liu, Jingwen ^c   Biddinger, Sudha B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Insulin; Insulin resistance; LDL receptor

Indexed keywords

ALBUMIN; ANTISENSE OLIGONUCLEOTIDE; INSULIN; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; STREPTOZOCIN; UNCLASSIFIED DRUG; PCSK9 PROTEIN, RAT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HALF LIFE TIME; HEPATOMA CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LOXP SITE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; ANIMAL; CELL LINE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; HALF-LIFE; HEPATOCYTES; INSULIN; MICE, KNOCKOUT; MICE, OBESE; RATS; RECEPTORS, LDL; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 84933038392     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305688     Document Type: Article

References (31)

1. Dietschy JM, Turley SD, Spady DK., Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993 34 1637 1659
2. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK., The PCSK9 decade. J Lipid Res 2012 53 2515 2524. doi: 10.1194/jlr.R026658
3. Seidah NG, Prat A., The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012 11 367 383
4. Abifadel M, Varret M, Rabès JP, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 34 154 156. doi: 10.1038/ng1161
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006 354 1264 1272. doi: 10.1056/NEJMoa054013
6. Marais DA, Blom DJ, Petrides F, Gouëffic Y, Lambert G., Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 2012 23 511 517. doi: 10.1097/MOL.0b013e3283587563
7. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH., Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009 94 2537 2543. doi: 10.1210/jc.2009-0141
8. Persson L, Gälman C, Angelin B, Rudling M., Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology 2009 150 1140 1146. doi: 10.1210/en.2008-1281
9. Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M., Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006 281 6211 6218. doi: 10.1074/jbc.M508582200
10. Ai D, Chen C, Han S, Ganda A, Murphy AJ, Haeusler R, Thorp E, Accili D, Horton JD, Tall AR., Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest 2012 122 1262 1270. doi: 10.1172/JCI61919
11. Niesen M, Bedi M, Lopez D., Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008 470 111 115. doi: 10.1016/j.abb.2007.11.009
12. Wade DP, Knight BL, Soutar AK., Regulation of low-density-lipoprotein-receptor mRNA by insulin in human hepatoma Hep G2 cells. Eur J Biochem 1989 181 727 731
13. Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, Croce KJ, Esquejo RM, Clish CB, Vicent D, Biddinger SB, Morbid Obesity Study Group Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun 2015 6 6498. doi: 10.1038/ncomms7498
14. Li S, Brown MS, Goldstein JL., Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010 107 3441 3446. doi: 10.1073/pnas.0914798107
15. Zelcer N, Hong C, Boyadjian R, Tontonoz P., LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009 325 100 104. doi: 10.1126/science.1168974
16. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR., Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000 6 87 97
17. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR., Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008 7 125 134. doi: 10.1016/j.cmet.2007.11.013
18. Miao J, Haas JT, Manthena P, Wang Y, Zhao E, Vaitheesvaran B, Kurland IJ, Biddinger SB., Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins. J Lipid Res 2014 55 659 667. doi: 10.1194/jlr.M043711
19. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA., Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987 68 231 240
20. Browning JD, Horton JD., Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010 51 3359 3363. doi: 10.1194/jlr.P009860
21. Folli F, Saad MJ, Backer JM, Kahn CR., Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 1993 92 1787 1794. doi: 10.1172/JCI116768
22. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW., Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008 49 399 409. doi: 10.1194/jlr.M700443-JLR200
23. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL., Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000 6 77 86
24. Haas ME, Attie AD, Biddinger SB., The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab 2013 24 391 397. doi: 10.1016/j.tem.2013.04.001
25. Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, Hirschey M, Vaitheesvaran B, Farese RV Jr, Kurland IJ, Graham M, Crooke R, Foufelle F, Biddinger SB., Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab 2012 15 873 884. doi: 10.1016/j.cmet.2012.05.002
26. Fisher SJ, Kahn CR., Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 2003 111 463 468. doi: 10.1172/JCI16426
27. Horton JD, Bashmakov Y, Shimomura I, Shimano H., Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA 1998 95 5987 5992
28. Moon YA, Liang G, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Brown MS, Goldstein JL, Horton JD., The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 2012 15 240 246. doi: 10.1016/j.cmet.2011.12.017
29. Rudling M, Angelin B., Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo. J Clin Invest 1993 91 2796 2805. doi: 10.1172/JCI116522
30. Lavine RL, Voyles N, Perrino PV, Recant L., The effect of fasting on tissue cyclic cAMP and plasma glucagon in the obese hyperglycemic mouse. Endocrinology 1975 97 615 620. doi: 10.1210/endo-97-3-615
31. Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schaper NC, Schalkwijk CG, Konrad RJ, Stehouwer CD., Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis 2011 217 263 267